Relmada Therapeutics Inc logo

RLMD - Relmada Therapeutics Inc Share Price

$34.38 -0.9  -2.5%

Last Trade - 24/02/21

Sector
Healthcare
Size
Mid Cap
Market Cap £406.0m
Enterprise Value £318.7m
Revenue £n/a
Position in Universe 3337th / 6713
Bullish
Bearish
Unlock RLMD Revenue
Momentum
Relative Strength (%)
1m -1.83%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -34.7%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the three months ended 30 September 2020,Relmada Therapeutics Inc revenues was not reported. Netloss increased 19% to $16.9M. Higher net loss reflectsResearch and development increase from $4.6M to $11.2M(expense), General and administrative increase of 18% to$5.9M (expense). Basic Earnings per Share excludingExtraordinary Items increased from -$2.57 to -$1.05.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

RLMD Revenue Unlock RLMD Revenue

Net Income

RLMD Net Income Unlock RLMD Revenue

Normalised EPS

RLMD Normalised EPS Unlock RLMD Revenue

PE Ratio Range

RLMD PE Ratio Range Unlock RLMD Revenue

Dividend Yield Range

RLMD Dividend Yield Range Unlock RLMD Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
RLMD EPS Forecasts Unlock RLMD Revenue
Profile Summary

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for central nervous system (CNS) disorders. Its product candidate includes dextromethadone (d-methadone), REL-1017, REL-1015 (LevoCap ER), REL-1028 (BuTab) and REL-1021 (MepiGel). d-methadone (dextromethadone, REL-1017) is an N-methyl-D-aspartate (NMDA) receptor antagonist. d-methadone is a new chemical entity (NCE) that is being developed for the treatment of central nervous system (CNS) diseases and other disorders. It is also being developed for the treatment of depression, ophthalmological disorders and/or other potential indications. REL-1015 (LevoCap ER) product candidate is an extended release, abuse deterrent, proprietary formulation of the opioid analgesic levorphanol. REL-1028 is a novel oral formulations of modified release buprenorphine. MepiGel is a topical dosage form of the local anesthetic mepivacaine.

Directors
Last Annual December 31st, 2019
Last Interim September 30th, 2020
Incorporated May 31, 2012
Public Since March 3, 2014
No. of Shareholders: 259
No. of Employees: 6
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 16,241,526
Free Float (0.0%)
Eligible for
ISAs
SIPPs
RLMD Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for RLMD
Upcoming Events for RLMD
Frequently Asked Questions for Relmada Therapeutics Inc
What is the Relmada Therapeutics Inc share price?

As of 24/02/21, shares in Relmada Therapeutics Inc are trading at $34.38, giving the company a market capitalisation of £406.0m. This share price information is delayed by 15 minutes.

How has the Relmada Therapeutics Inc share price performed this year?

Shares in Relmada Therapeutics Inc are currently trading at $34.38 and the price has moved by -25.29% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Relmada Therapeutics Inc price has moved by -39.71% over the past year.

What are the analyst and broker recommendations for Relmada Therapeutics Inc?

There are no analysts currently covering Relmada Therapeutics Inc.

When will Relmada Therapeutics Inc next release its financial results?

Relmada Therapeutics Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the Relmada Therapeutics Inc dividend yield?

Relmada Therapeutics Inc does not currently pay a dividend.

Does Relmada Therapeutics Inc pay a dividend?

Relmada Therapeutics Inc does not currently pay a dividend.

When does Relmada Therapeutics Inc next pay dividends?

Relmada Therapeutics Inc does not currently pay a dividend.

How do I buy Relmada Therapeutics Inc shares?

To buy shares in Relmada Therapeutics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Relmada Therapeutics Inc?

Shares in Relmada Therapeutics Inc are currently trading at $34.38, giving the company a market capitalisation of £406.0m.

Where are Relmada Therapeutics Inc shares listed? Where are Relmada Therapeutics Inc shares listed?

Here are the trading details for Relmada Therapeutics Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: RLMD
What kind of share is Relmada Therapeutics Inc?

Based on an overall assessment of its quality, value and momentum, Relmada Therapeutics Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Relmada Therapeutics Inc share price forecast 2021?

Shares in Relmada Therapeutics Inc are currently priced at $34.38. At that level they are trading at 78.14% discount to the analyst consensus target price of 0.00.

Analysts covering Relmada Therapeutics Inc currently have a consensus Earnings Per Share (EPS) forecast of -3.625 for the next financial year.

How can I tell whether the Relmada Therapeutics Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Relmada Therapeutics Inc. Over the past six months, the relative strength of its shares against the market has been -7.27%. At the current price of $34.38, shares in Relmada Therapeutics Inc are trading at -7.47% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Relmada Therapeutics Inc PE Ratio?

We were not able to find PE ratio data for Relmada Therapeutics Inc.

Who are the key directors of Relmada Therapeutics Inc?

Relmada Therapeutics Inc's management team is headed by:

Sergio Traversa - CEO
Charles Casamento - CHM
Maged Shenouda - CFO
Paul Kelly - IND
Charles Ence - CAO
Eric Schmidt - IND
John Glasspool - IND
Marc de Somer - SVP
Paolo Manfredi - CSO
Marco Pappagallo - OTH
Who are the major shareholders of Relmada Therapeutics Inc?

Here are the top five shareholders of Relmada Therapeutics Inc based on the size of their shareholding:

Avoro Capital Advisors LLC Investment Advisor/Hedge Fund
Percentage owned: 9.39% (1.53m shares)
RTW Investments L.P. Investment Advisor/Hedge Fund
Percentage owned: 9.31% (1.51m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 6.55% (1.06m shares)
VR Adviser, LLC Venture Capital
Percentage owned: 4.12% (668k shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 4.08% (663k shares)
Similar to RLMD
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.